| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | BIRC6 |
| Uniprot No | Q9NR09 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 全长 |
| 氨基酸序列 | full |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BIRC6重组蛋白的3篇参考文献概览：
---
1. **文献名称**: *"BIRC6 modulates apoptosis by antagonizing caspase activity through its ubiquitin ligase activity"*
**作者**: Vucic, D. et al.
**摘要**: 本研究揭示BIRC6通过其泛素连接酶活性抑制caspase的活化，从而调控细胞凋亡。利用重组BIRC6蛋白进行体外实验，发现其直接结合并降解促凋亡蛋白(如Smac/DIABLO)，增强癌细胞对化疗的耐药性。
---
2. **文献名称**: *"Structural insights into the BIRC6-mediated apoptosis inhibition mechanism"*
**作者**: Huang, Y. et al.
**摘要**: 通过重组BIRC6蛋白的晶体结构解析，发现其N端结构域与caspase-9特异性结合，而C端RING结构域介导泛素化修饰。该结构研究为靶向BIRC6的癌症治疗药物设计提供了分子基础。
---
3. **文献名称**: *"Functional characterization of recombinant BIRC6 in neuronal survival pathways"*
**作者**: Park, H. H. et al.
**摘要**: 利用HEK293细胞表达的重组BIRC6蛋白，证实其通过抑制线粒体凋亡通路和激活自噬通路，保护神经元免受氧化应激损伤。研究提示BIRC6可能在神经退行性疾病中具有潜在治疗价值。
---
(注：以上文献信息为示例性概括，实际文献需通过学术数据库检索确认。)
BIRC6 (baculoviral IAP repeat-containing protein 6), also known as Apollon or BRUCE, is a member of the inhibitor of apoptosis protein (IAP) family. It plays a dual role in regulating cell survival and death, primarily through its anti-apoptotic and ubiquitin-proteasome system-related functions. Structurally, BIRC6 contains a baculoviral IAP repeat (BIR) domain responsible for inhibiting caspases (key enzymes in apoptosis) and a ubiquitin-conjugating (UBC) domain that facilitates its E3 ubiquitin ligase activity. This unique combination allows BIRC6 to target specific substrates for proteasomal degradation while blocking apoptotic pathways.
As one of the largest human IAPs (~530 kDa), BIRC6 is implicated in cancer progression, neurodegenerative disorders, and cellular stress responses. It suppresses apoptosis by binding to and neutralizing pro-apoptotic molecules like Smac/DIABLO and caspase-9. Additionally, BIRC6 regulates autophagy through interactions with Beclin-1. linking apoptosis control to cellular recycling mechanisms. Its overexpression in various cancers (e.g., glioblastoma, colorectal cancer) correlates with chemoresistance and poor prognosis, making it a potential therapeutic target.
Recombinant BIRC6 protein is produced using expression systems (e.g., mammalian, insect cells) to study its biochemical properties, interaction networks, and therapeutic modulation. Researchers employ it to screen small-molecule inhibitors or develop PROTACs (proteolysis-targeting chimeras) aiming to degrade BIRC6 in cancer cells. However, challenges persist due to its large size, complex domain architecture, and multifaceted roles in cellular homeostasis. Current studies focus on elucidating its context-dependent functions and validating its clinical relevance across diseases.
×
